Psoriasis

In patients with high levels of VEGF-A and more severe psoriasis, downregulation of blood vessel area is more abrupt.

Nicholas Brownstone, MD, comments on how newer treatments in plaque psoriasis can impact residency training.

Dawn L. Sammons, DO, FAOCD, FAAD, shares her approach to using topical vs systemic therapy in plaque psoriasis, focusing on patient preference as the driving factor for treatment selection.

Tj Chao, MPAS, and Lauren Miller, MPAS, highlight comorbidities that caregivers should consider when treating patients with plaque psoriasis (PP).

Lauren Miller, MPAS, and Tj Chao, MPAS, discuss key factors to consider for plaque psoriasis (PP) treatment.

New research into the disease’s pathogenesis may inform future treatment options.

As many as 1 in 5 patients with psoriasis experience depression as a comorbidity.

A plethora of oral and topical treatments are available for patients, according to Stein Gold’s SCALE 2023 sessions.

Experts discuss the role and importance of physician assistants in the treatment and care of plaque psoriasis (PP).

Tj Chao, MPAS, and Lauren Miller, MPAS, discuss the symptoms of plaque psoriasis (PP) and why it may be difficult to diagnose.

Brad Glick, DO, FAOCD, highlights topical therapy as a targeted treatment of plaque psoriasis.

Benjamin Lockshin, MD, FAAD, comments on how the evolution of the pathophysiology of plaque psoriasis has led to more targeted therapies to treat the disease.

The intention is to expedite the development and review of the drug helping adults with generalized pustular psoriasis.

Inhibitor etanercept alleviated pathological changes and inflammation in induced psoriasis.

Oral vitamin D supplementation does not appear to have an effect on disease severity for those with low 25-hydroxyvitamin D (25[OH]D) levels.

Researchers compiled future research directions and therapeutic and clinical developments in psoriasis.

This will be the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint.

It has been hypothesized that some lipid-lowering drugs are disease-modifying for psoriasis, and the use of lipid-lowering drugs in the management of psoriasis symptoms is currently being explored

An expert in dermatology shares his thoughts on the educational and unmet needs in the identification and management of patients with GPP.

Dr David Kaplan discusses the current treatment options for GPP; highlighting the long time to treatment repose, need for combination treatment, and of standard of care guidelines.

David Kaplan, MD, provides an overview of generalized pustular psoriasis, and comments on his differential diagnosis process and key symptomology.

AbbVie announced study results demonstrating efficacy in patients with a history of previous interleukin-17 inhibitor therapy.

Researchers say the impacts may be more harmful than those caused by industrial air pollutants.

Dr Raj Chovatiya discusses a recently approved therapeutic agent, spesolimab, as a valuable addition to the GPP treatment landscape.

An expert dermatologist reviews the currently available agents for treatment of GPP and highlights the unmet needs in this space.

Raj Chovatiya, MD, PhD, provides an overview of the factors he uses to lead to a diagnosis of generalized pustular psoriasis (GPP).

An expert in dermatology shares his insights into the management considerations with traditionally utilized treatments for generalized pustular psoriasis and discusses the impact of a recent approval in this space.

Dr Michael Payette discusses the patient QoL impacts and burden of generalized pustular psoriasis.

Michael Payette, MD, MBA, FAAD provides an overview of generalized pustular psoriasis, highlighting the challenges in the diagnosis of patients with this condition.

Pregnant women with atopic dermatitis and psoriasis may require special treatment considerations.